Evidence map›Paper›PMID 41876742›Full record

ArticleThe EMBO journal2026

Author Correction: Residual apoptotic activity of a tumorigenic p53 mutant improves cancer therapy responses.

Oleg Timofeev, Boris Klimovich, Jean Schneikert, Michael Wanzel, Evangelos Pavlakis, Julia Noll, Samet Mutlu, Sabrina Elmshäuser, Andrea Nist, Marco Mernberger and 6 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

16 authors.

Oleg TimofeevInstitute of Molecular Oncology, Philipps-University, Marburg, Germany.
Boris KlimovichInstitute of Molecular Oncology, Philipps-University, Marburg, Germany.
Jean SchneikertInstitute of Molecular Oncology, Philipps-University, Marburg, Germany.
Michael WanzelInstitute of Molecular Oncology, Philipps-University, Marburg, Germany.
Evangelos PavlakisInstitute of Molecular Oncology, Philipps-University, Marburg, Germany.
Julia NollInstitute of Molecular Oncology, Philipps-University, Marburg, Germany.
Samet MutluInstitute of Molecular Oncology, Philipps-University, Marburg, Germany.
Sabrina ElmshäuserInstitute of Molecular Oncology, Philipps-University, Marburg, Germany.
Andrea NistGenomics Core Facility, Philipps University, Marburg, Germany.
Marco MernbergerInstitute of Molecular Oncology, Philipps-University, Marburg, Germany.
Boris LampGenomics Core Facility, Philipps University, Marburg, Germany.
Ulrich WenigInstitute of Pathology, Justus Liebig University, Giessen, Germany.
Alexander BrobeilInstitute of Pathology, Justus Liebig University, Giessen, Germany.
Stefan GattenlöhnerInstitute of Pathology, Justus Liebig University, Giessen, Germany.
Kernt KöhlerInstitute of Veterinary Pathology, Justus Liebig University, Giessen, Germany.
Thorsten StieweInstitute of Molecular Oncology, Philipps-University, Marburg, Germany. thorsten.stiewe@uni-marburg.de.ORCID http://orcid.org/0000-0003-0134-7826

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID41876742
PMCPMC13144674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.